Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, provides the latest developments and insights. Support the show

What will be the impact of US tariffs on CDMOs of injectables and on the decision-making of pharma companies on in-sourced/outsourced activity overall and in key geographic markets: Europe, Canada, India and China? How will major segments, innovator drug and generics/biosimilar be affected? Featuring Ian Tzeng, Managing Director and Partner, L.E.K. Consulting, where he focuses on healthcare and life sciences, including pharmaceuticals and vaccines, and leads L.E.K.’s Pharmaceutical Con...

Biotech companies are an important source for innovation and product development for larger companies and are an important customer base of CDMOs/CMOs. Capital flow in the biotech sector, an important barometer of the financial health of the sectors, has been under pressure with macro factors in the US on tariffs, tax & monetary policy, and drug pricing reforms contributing to uncertainty. But will the tide turn? Featuring Arda Ural, EY America Life Sciences Leader, Ernst & Young (EY)...

As evolving US trade policy looms, what are the demand–supply fundamentals now in the global market for active pharmaceutical ingredients (APIs)? A look at the demand side—size, growth rates, and trends— and the supply side—key segments for global API manufacturing and its geographic dispersion. Plus, examining the impact of potential tariffs on manufacturing and supply chains. Support the show

What is industry capacity utilization for biomanufacturing among the major systems/platforms (mammalian, microbial, and advanced therapies, and is there too much capacity or is the market tight? Is biomanufacturing outsourcing up or down? Are biopharma companies outsourcing more or less? Plus the impact on evolving trade policy on biomanufacturing supply chains. Featuring: Eric Langer, MBA, Managing Partner & President, BioPlan Associates and Renaud Jacquemart, PhD, MBA, Senior Advi...

How are supply and demand shaping up for sterile manufacturing and aseptic fill–finish in the CDMO/CMO sector? Is a capacity crunch or capacity ease in the making? And how will hot-product areas, such as GLP-1 agonist impact market fundamentals. Featuring Ian Tzeng, Managing Director and Partner, L.E.K. Consulting, where he focuses on healthcare and life sciences, including pharmaceuticals, vaccines, and leads L.E.K.’s Pharmaceutical Contract Services practice. Support the...

What will be the key issues shaping bio/pharma supply chains in 2025? Looking at the impact of potential changes in US tariff and trade policy. Plus, what lies ahead in product-specific supply chains for sterile injectables and antibody drug conjugates. And the latest on how companies are advancing upstream supplier risk monitoring and predictive risk planning, including through digitalization and AI. Featuring: Derron Stark, EY-Parthenon Partner, Strategy & Transactions – Health S...

What are some key trends and issues arising in parenteral drug development and manufacturing? From more complex molecules and modalities and sterile drug-product capacity market shifts, DCAT Value Chain Insights takes an inside look. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers in drop down menu in audio player above) Major trends in parenteral drug development Long peptides in NDAs and BLAs New complex modalities Sterile drug-...

As 2023 comes to a close, what were the largest mergers and acquisitions and expansions made by CDMOs/CMOs in 2023? DCAT Value Chain Insights looks at which companies topped the headlines this year and the leading moves they made. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers in drop down menu in audio player above) BaxterSamsung BiologicsLotte BiologicsFujifilm Diosynth BiotechnologiesLonza CambrexExpansions in peptides, oligonucleotides...

As we near the mid-year mark, what have been the key moves—mergers and acquisitions, expansions, and new CDMOs entering the market—thus far in 2023? DCAT Value Chain Insights takes an inside look on what is on the industry’s radar. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers in drop down menu in audio player above) BaxterLarge-scale biomanufacturing expansions continue Samsung BiologicsLotte BiologicsFujifilm Diosynth BiotechnologiesLo...

The European Commission has issued its long-awaited proposal to reform pharmaceutical legislation in the EU, the first major overhaul in 20 years, which includes new requirements to address drug shortages and secure supply chains. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers in drop down menu in audio player above) Proposed reforms Security of supply and supply-chain reforms Specific proposals Podcast Sponsor: BIOVECTRA Links:...

Increased demand in biologic-based drug development is a key factor driving demand for parenteral drug manufacturing. What are key trends and expansions by CDMO/CMOs in parenteral drug manufacturing? DCAT Value Chain Insights rounds up the latest developments among CDMO/CMOs. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers in drop down menu in audio player above) Recent expansion projects Baxter BioPharma Solutions Vetter R...

What are noteworthy trends in drug delivery and drug-product development in key dosage forms: solid dosage and parenteral drugs? A look at key technology advances and recent new drug approvals. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers in drop down menu in audio player above) Recent trends: new drug approvalsTechnology advancesEnable Injections’ on-body subcutaneous drug-delivery systemLilly’s and Triastek’s pact for 3-D printing for oral drug de...

Growth in the oncology drug market continues to spur demand for high-potency API manufacturing. Which CDMOs/CMOs are expanding? DCAT Value Chain Insights rounds up the latest investments. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers in drop down menu in audio player above) A roundup of recent investments in HPAPI manufacturing WuXi STA MilliporeSigmaPiramal Pharma SolutionsCambrexHAS Healthcare Advanced SynthesisAGC Fine ChemicalsLonzaCarb...

A newly released DCAT benchmarking study examines the targets and progress made by bio/pharma companies and suppliers in reaching their sustainability goals. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers in drop down menu in audio player above) Sustainability and the bio/pharma supply chainKey finding: External stakeholders drive effortsKey finding: Supply-chain sustainability lags internal effortsKey finding: Measuring achievement a major challengeK...

Capital investments are ramping up in biomanufacturing, which continues to be an active area for CDMOs/CMOs in both traditional biologics and new modalities. Which companies are expanding? For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers in drop down menu in audio player above) A roundup of expansion activityFujifilm Diosynth BiotechnologiesSamsung BiologicsLonzaBoehringer IngelheimThermo Fisher ScientificCatalentWuXi Biologics Sponsor: BIOVECTRA...

A DCAT Week program brings together leading Bio/Pharma executives to offer their perspectives on how Bio/Pharma companies and their suppliers are adjusting supply practices now and in the near term. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers) Supply-chain challenges and solutions (1:13) Sponsor: LGM Pharma Links: Subscribe to our e-newsletter at www.dcatvci.org Follow us on Twitter @DCATvci Support the show Support the show

Parenteral drugs have accounted for between 40% and 50% of new drug approvals over the past five years. CDMOs/CMOs continue to expand. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers in drop down menu in audio player above) Active area of investment (1:13)Baxter BioPharma Solutions (1:25)PCI Pharma Services (2:07)Alcami (3:22)Catalent (4:31)Vetter (5:47)Thermo Fisher Scientific (6:41)Grand River Aseptic Manufacturing (7:35)Lonza (9:12)Curia (9:50)Jubil...

Escalating energy prices are impacting global manufacturing and supply chains. In the EU, leaders are proposing measures to alleviate pricing pressures. What’s the plan? Key topics: (see Chapter Markers) Economic recovery brings pricing pressuresRising energy costs and the bio/pharma manufacturing value chain Rising energy costs: call for action in the EU Ripple effect throughout industrial supply chainsActions proposed by the European CommissionProposals for energy-price reliefSp...

Which modality, small molecules or biologics, leads among the top-selling products? A look at the top-selling products industry-wide and blockbusters from select leading bio/pharma companies provides the answer. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers) Modality of top-selling productsNew drug approvals: small molecules versus biologicsPotential blockbusters: small molecules and biologicsBiogen’s and Eisai’s aducanumabArgenx’s efgartigimodBristo...